Company intelligence / Profile preview

Suzhou Shengdia Biomedical

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

The company has received multiple approvals for clinical trials of innovative antibody and fusion protein therapeutics for oncology and autoimmune indications, with pipeline molecules advancing through Phase 1–3 and most programs focusing on novel targets or modalities. No products have been approved for sale yet; clinical trials are ongoing.

Therapeutic areas: OncologyImmunologyCardiovascular
Modalities: AntibodyMonoclonal antibodyAntibody-drug conjugateBispecific monoclonal antibodySmall moleculeRecombinant fusion protein
Industry: Pharma

Partnerships

Strong relationship with parent company Hengrui PharmaceuticalCollaborates with other Hengrui subsidiaries, e.g., Shanghai Shengdi Pharmaceutical Co., Ltd.

Beyond the preview

Go deeper on Suzhou Shengdia Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou Shengdia Biomedical.

Explore the full profile